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APPENDIX. CONFERENCE DISCUSSION
Dr A. Bochenek (Katowice, Poland): I think it is a very important paper
because it shows us that TAVI in a failing aortic valve prosthesis is possible,
and is possible during the femoral and during the apical approach.
You have pointed out the limitation of this study, but this study, together
with the previous study by Pasic from the Hetzer centre and the groups of
Walther and Mohr, gives us more valid information about the early problems
and longer term results.
In this study the technical success was 94%, but procedural success,
deﬁned as adequate valve placement and function on discharge from the
hospital, was only 50%. The primary safety end point, including MACCE, was
only 44%, early mortality 11%, one-year mortality, 28%.
First question. How many patients in your group were disqualiﬁed com-
pletely from surgery, and in how many patients did the surgeon have a role
in the decision to disqualify the patient from surgery? I know that this is a
very difﬁcult group, and we are very happy that somebody is helping us to
sort out this problem in our department, but the results are not good. In a
good centre, the results, even with a difﬁcult operation, can be better. How
many patients were completely disqualiﬁed from surgery?
The other question is the approach. We know from the other study that
the apical approach maybe is easier because the transapical approach is inde-
pendent of the degree of patient pericardial disease and advancing the wire
antegrade is easy, repeatable, and simple. How many patients were disquali-
ﬁed because of a very calciﬁed aortic and iliac vessel in this group?
One more question about the valvuloplasty. What was the indication for
valvuloplasty before the deployment of this valve?
Dr Mueller: I fully agree that the results are not perfect. There is need for
improvement. The main thing I think is that the positioning of the CoreValve
in a small bioprosthetic valve is cumbersome, because there is a very strong
tendency to move inwards, and in many of these what we did ﬁnd were
negative results due to this fact. Perhaps the development of a smaller
CoreValve could overcome this problem. The smaller CoreValve will come.
In our centre, we decided if we do have very small surgical valves implanted,
we prefer an Edwards prosthesis implanted, and we do have better results
then.
We presented and discussed all of our patients with our cardiovascular
team. All but one were not accepted for surgery by them. But this was a
study and we could treat them.
Regarding your other question, in the ﬁrst two patients with pure aortic, or
stenosis of the bioprosthetic valve, we did a valvuloplasty because we were
used to it, and in the next, we avoided it.
Dr F. Mohr (Leipzig, Germany): I think you already made a very good point,
that a balloon-expandable valve of the same size, like the bioprosthesis most
likely, works much better than a self-expanding type design in our hands
also, and there should be a clear message here.
And I also want to point to a paper, which I do think is important, con-
cerning the structure and leaf pathology of some valve types which have a
very high proﬁle, like, for example, the Mitroﬂow and/or the Trifectam,
implanted in a small root, are contraindications for a kind of TAVI, because it
is very likely that by dilating the frame a little bit you may occlude the coron-
ary ostia. So these are things we should consider in deﬁning which is the
optimal type of TAVI route. I think transapical is a very good one since you
can approach the mitral as well, but also I think you made the point that the
self-expanding type is not the optimal design. Aortic regurgitation with a
balloon-expandable type valve does not occur in the frame, and I think this is
advantageous. But, still, we need to look at the valves we have implanted at
the very beginning, because from that experience you can decide whether
you can or cannot do it.
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Transcatheter aortic valve implantation (TAVI) has become a
reliable treatment modality for aortic valve stenosis. More
than 10 years after the ﬁrst implantation, it is still debatable
which patients may beneﬁt from TAVI compared with surgical
aortic valve replacement (SAVR) although the Partner A study
[1] described a well-deﬁned patient population as optimal
candidates for TAVI. Evidence for further indications is still
needed.
Aortic valve re-operation may carry a higher perioperative risk
compared with ﬁrst-time SAVR because patients are older but
technically speaking, redo-SAVR is not extremely demanding [2].
Transcatheter aortic valve-in-valve implantation (ViV TAVI) might
S.H. Ong et al. / European Journal of Cardio-Thoracic Surgery276
be of particular interest for some patients scheduled for SAVR as
a redo-procedure, for instance, in those with patent coronary
artery grafts.
The present study [3], which was sponsored by Medtronic,
reports on 18 patients from three different centres in Germany
who received a CoreValve™ ViV TAVI to treat a degenerated
aortic bioprosthetic valve.
Including patients older than 75 years with either a logistic
EuroSCORE of ≥15% or one additional self-deﬁned risk factor (i.e.,
atrial ﬁbrillation) might appear rather arbitrary. But with an overall
logistic EuroSCORE of 34%, patient selection seems adequate.
Unfortunately, more accurate STS scores are lacking. Procedural
success was achieved when echocardiography showed adequate
valve placement and function at discharge or on POD 10 without
any composite Major Adverse Outcomes (MAE) until discharge.
Indications for TAVI in the presence of a degenerated tissue
valve were isolated regurgitation in 33% of patients, isolated
stenosis in 28% and a combination of both in 39%. The average
time interval since primary AVR was 7 years (range 1–16 years).
Valve-in-valve TAVI represents an attractive and less invasive
alternative to conventional redo-surgery and some technical
details, as, for instance, the radio-opaque frame of the in situ
tissue valve facilitates accurate valve-in-valve deployment.
Moreover, ﬂuoroscopic orientation requires smaller doses of
contrast and also allows for ViV implantation in pure regurgita-
tion of the tissue valve. Sizing is easier because the diameter of
the prior valve is usually known from the time of surgery. Finally,
the landing zone is more circular and decreases the risk of para-
valvular leakage, and annular tear from overexpansion is unlikely.
The risk of a permanent aortic valve (AV) Block III with conse-
quent pacemaker implantation is low.
Although ViV TAVI in stented bioprosthesis may be technically
less demanding, decision making requires additional experience
and expertise; for instance, a profound understanding of the
type of surgical bioprosthesis and its construction is important.
In contrast to stented tissue valves, stentless valves pose a unique
challenge for ViV TAVI. The absence of struts, sewing ring and
ﬂuoroscopic landmarks increase the procedural complexity. In this
series, 44% of the ViV procedures were performed in stentless xeno-
grafts. This might be the reason for the reported 30% AV blocks
with consequent pacemaker implantations in more than 10%.
Further understanding of how a bioprosthesis degenerates is
essential. The leaﬂet’s changes increase the difﬁculty of retro-
grade passing. A degenerated prosthetic leaﬂet may generate
more embolic events since the debris are sometimes very loose
and might detach more easily. This is the reason why experts
generally do not recommend balloon pre-dilatation.
It is surprising that the authors performed pre-dilatation in up
to 75% of the patients in this series with stenotic degeneration
and the fact that two neurological events occurred only in
patients with stenotic degeneration points towards the increased
risk of embolization after pre-dilatation.
The overall incidence of 30-day Major Adverse Cardiac and
Cerebrovascular Events (MACCE) (39%) and 30-day composite
MAE (44%) is high but a 30-day mortality of 12% in the presence
of high-risk patients with a predicted EuroSCORE mortality of
34% is acceptable.
Transvalvular gradient and effective oriﬁce area (EOA) are
further important aspects that deserve detailed attention
when performing ViV TAVI. With a baseline mean gradient of
37 mmHg and a valve oriﬁce area of 0.9 cm2, haemodynamic
results were encouraging: mean gradient decreased to 19
mmHg at one year and EOA increased to 1.5 cm2. Similar
results were reported in the literature after ViV with either the
Edwards Sapiens™ or the Medtronic CoreValve™ device [4]. But
these results also indicate that ViV cannot be repeated several
times as transvalvular gradients might then not decrease
sufﬁciently.
TAVI indications will most likely expand in the future. With
the current TAVI data, the feasibility of a later ViV TAVI pro-
cedure alone does not justify the implantation of tissue
valves into younger patients (<60-65 years). The goal of each
valve procedure should remain one, and only one, proced-
ure for the rest of the patient’s life (ESC Guidelines).
Decision making for a patient with a degenerated tissue
valve prosthesis is substantially enhanced by the multidiscip-
linary heart team approach. Taking advantage of the joint
expertise of the cardiac surgeon and the interventional car-
diologist, ultimately enhances patients safety.
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